NCT00579501 - Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions

Liposarcoma,Myxoid

Interventions

DRUG

Trabectedin

Trabectedin 1.5 mg/m\^2 over a 24-hour iv infusion every 3 weeks for a minimum of 3 and a maximum of 6 cycles of trabectedin.

DRUG

Dexamethasone

Dexamethasone 20 mg iv will be administered within 30 minutes before start of each trabectedin iv infusion

Trial Locations (8)

Coeur d'Alene

Park Ridge

Iowa City

Boston

Bourdeaux

Lyon

Villejuif

Mannheim